Immutep Limited

Equities

IMM

AU000000IMM6

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 07:10:51 17/07/2024 BST			5-day change	1st Jan Change
0.295 ^AUD	-1.67%		+1.72%	-14.49%

02:53pm	Immutep Receives Dutch Regulatory Approval to Begin Human Testing of Potential Autoimmune Treatment	MT
02:42am	Immutep Secures Regulatory Clearance for Phase 1 Antibody Study in Autoimmune Diseases; Shares Up 3%	MT

Prima BioMed Ltd.'s Can-004 Clinical Trial Amendment Approved in Belgium

January 17, 2014 at 01:00 pm

Prima BioMed Ltd. announced that the amended CAN-004 protocol was approved by the Belgian Federal Agency for Medicines and Health Products. This is the first regulatory agency to approve the amended CVac(TM) clinical trial design. CAN-004 is a multicentre, randomized, phase 2 trial of CVac for the maintenance treatment of epithelial ovarian cancer in remission.

Latest news about Immutep Limited

Immutep Receives Dutch Regulatory Approval to Begin Human Testing of Potential Autoimmune Treatment	01:53pm	MT
Immutep Secures Regulatory Clearance for Phase 1 Antibody Study in Autoimmune Diseases; Shares Up 3%	01:42am	MT
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	07-12	MT
Sector Update: Health Care Stocks Rise in Afternoon Trading	07-12	MT
Top Midday Gainers	07-12	MT
Sector Update: Health Care Stocks Mixed Premarket Friday	07-12	MT
Sector Update: Health Care	07-12	MT
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Friday as Big Bank Earnings Kick Off Earnings Season	07-12	MT
Top Premarket Gainers	07-12	MT
Immutep Achieves 'Positive' Results From Cohort B of Phase 2B Cancer Trial; Shares Rise Pre-Bell	07-12	MT
Rising US Rate Cut Bets Lift Australian Shares to Record High	07-12	MT
Immutep Surges 19% Following Positive Results in Head, Neck Cancer Trial	07-12	MT
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative Pd-L1 Expression	07-11	CI
Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer	06-28	CI
ADRs End Flat; Alarum Technologies Climbs 26%	06-27	DJ
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data	06-27	MT
Baird Trims Immutep Price Target to $6 From $7, Maintains Outperform Rating	06-27	MT
Immutep Reports Positive Results in Drug Combination Trial for Head, Neck Cancer	06-27	MT
Immutep Gets Exclusive Rights to Develop, Commercialize New Anti-LAG-3 Small Molecules	06-25	MT
Immutep Signs Agreement with Cardiff University for Development Cancer Treatment	06-25	MT
Immutep Completes Nearly AU$11 Million Retail Entitlement Offer	06-24	MT
Immutep Completes Stock Offering	06-05	MT
Immutep, Merck Collaborate on Trial for Lung Cancer Therapy	06-03	MT
Immutep, Merck Partner for Efti and Keytruda Combo in Lung Cancer Trial	06-03	MT
Immutep Raising AU$100 Million for Phase Three Trial	06-03	MT

Chart Immutep Limited

Duration

Period

More charts

Company Profile

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3âs ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - CG Growth Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Immutep Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3 AUD

Average target price

0.976 AUD

Spread / Average Target

+225.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMMUTEP LIMITED	-14.49%	287M
MODERNA, INC.	+23.97%	47.96B
IQVIA HOLDINGS INC.	+2.00%	42.45B
LONZA GROUP AG	+44.25%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+27.35%	31.6B
ICON PUBLIC LIMITED COMPANY	+21.64%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+53.93%	14.56B
MEDPACE HOLDINGS, INC.	+46.41%	14.14B
BIO-TECHNE CORPORATION	+3.95%	12.58B

Other Biotechnology & Medical Research